Publications

5674 Results

Impact of supplemental site grants to increase African American accrual for SELECT. PMID: 20156960

Authors
ED Cook;KB Arnold;JA Hermos;W McCaskill-Stevens;S Moody-Thomas;JL Probstfield;SJ Hamilton;RD Campbell;K Anderson;LM Minasian
Journal / Conference
Clinical Trials 7(1):90-99
Year
2010
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000

Results of Southwest Oncology Group phase II evaluation (study S0031) of ZD 1839 for advanced transitional cell carcinoma of the urothelium [PMID19888985]

Authors
DP Petrylak;CM Tangen;PJ Van Veldhuizen;JW Goodwin;PW Twardlowski;JN Atkins;SR Dakhil;MK Melnik Lange;ED Crawford
Journal / Conference
British Journal of Urology International 105(3):317-321;
Year
2010
Research Committee(s)
Genitourinary
Study Number(s)
S0031

Phase II trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508

Authors
JI Clark;J Moon;L Hutchins;JA Sosman;WM Kast;DM Da Silva;PY Liu;JA Thompson;LE Flaherty;VK Sondak
Journal / Conference
Cancer 116(2):424-431; online 11/13/09;
Year
2010
Research Committee(s)
Melanoma
PMID
PMID19918923
PMC
PMC2811758
Study Number(s)
S0508

Prognostic value of regulatory T-cells, lymphoma associated macrophages and Mum-11 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study [PMC2875547; PMID19875761]

Authors
JW Sweetenham;B Goldman;M LeBlanc;JR Cook;RR Tubbs;OW Press;DG Maloney;RI Fisher;LM Rimsza;ED Hsi
Journal / Conference
Annals of Oncology 21(6):1196-1202;
Year
2010
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8809, S9800, S9911

A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): a Southwest Oncology Group study (S0331)

Authors
WE Samlowski;J Moon;RJ Tuthill;MC Heinrich;SA Merl;RC DeConti;JA Thompson;MT Witter;LE Flaherty;VK Sondak
Journal / Conference
American Journal of Clinical Oncology, Oct; 33(5):495-499;
Year
2010
Research Committee(s)
Melanoma
PMID
PMID20019577
PMC
PMC2978644
Study Number(s)
S0331

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients [PMC2834472; PMID20124181]

Authors
M. Van Glabbeke;J. Verweij;J-Y. Blay;M. Debiec-Rychter;G.D. Demetri;M.C. Heinrich;E.C. Borden;B.G. Redman;C.D. Blanke;C. Rankin;J.J. Crowley;P. Casali;M. von Mehren;C. Fletcher;J. Fletcher;K. Owzar;J. Zalcberg;J. Simes;V. Bramwell-Wesley
Journal / Conference
Journal of Clinical Oncology 28(7):1247-1253;
Year
2010
Research Committee(s)
Sarcoma
Study Number(s)
S0033

Multiplexed assessment of the Southwest Oncology Group directed intergroup breast cancer trial S9313 by AQUA show both high and low levels of HER2 are associated with poor outcome [PMC2843456; PMID20150438]

Authors
M Harigopal;W Barlow;G Tedeschi;P Porter;I Yeh;C Haskell;R Livingston;G Hortobagyi;G Sledge;C Shapiro;J Ingle;D Rimm;DF Hayes
Journal / Conference
American Journal of Pathology 176(4):1639-1647;
Year
2010
Research Committee(s)
Breast
Study Number(s)
SWOG-9313

A phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small cell lung cancer (NSCLC): an NCCTG and SWOG study, N0426 [PMC2815996; PMID19841321]

Authors
AA Adjei;SJ Mandrekar;GK Dy;JR Molina;A Adjei;GR Gandara;KL Ziegler;PJ Stella;KM Rowland;SE Schild;RG Zinner
Journal / Conference
Journal of Clinical Oncology 28(4):614-619
Year
2010
Research Committee(s)
Lung
Study Number(s)
N0426

Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with cyclosporine, in older patients with previously untreated acute myeloid leukemia (AML) [PMID 19821823; PMC2967366]

Authors
TR Chauncey;H Gundacker;M Shadman;AF List;SR Dakhil;HP Erba;ML Slovak;I-M Chen;CL Willman;K Kopecky;FR Appelbaum
Journal / Conference
British Journal of Haematology 148(1):48-58;
Year
2010
Research Committee(s)
Leukemia
Study Number(s)
S0112, S0301

Expression of p21 protein predicts clinical outcome in DLBCL patients treated with R-CHOP: a prospective ECOG and SWOG correlative study of E4494 [PMC2865202; PMID20371683]

Authors
JN Winter;V Aurora;V Variakojis;B Nelson;M Krajewska;L Zhang;T Habermann;RI Fisher;WR Macon;M Chhanabhai;RE Felgar;ED Hsi;LJ Medeiros;JK Weick;EA Weller;A Melnick;JC Reed;SJ Horning;RD Gascoyne
Journal / Conference
Clinical Cancer Research 16(8):2435-2442;
Year
2010
Research Committee(s)
Lymphoma
Study Number(s)
E4494